
  
    
      
        
        “ Publishing_NN results_NNS in_IN traditional_JJ paper_NN based_VBD way_NN in_IN a_DT journal_NN hides_NNS too_RB much_JJ
        information_NN ._.” This_DT is_VBZ the_DT verdict_NN of_IN Markus_NNP Ruschhaupt_NNP and_CC colleagues_NNS who_WP ,_, in_IN a_DT paper_NN in_IN 
        Statistical_NNP Applications_NNS in_IN Genetics_NNP and_CC Molecular_NNP Biology_NNP (_( 3_CD :_: article_NN
        37_CD )_) ,_, discuss_VBP a_DT paradigm_NN for_IN the_DT presentation_NN of_IN complex_JJ data—in_NN this_DT case_NN ,_, from_IN microarray_NN
        analyses_NNS ._. The_DT title_NN of_IN the_DT article_NN ,_, “ A_DT Compendium_NNP to_TO Ensure_NNP Reproducibility_NNP in_IN
        High-_NNP Dimensional_NNP Classification_NNP Tasks_NNP ,_,” may_MD not_RB lend_VB itself_PRP easily_RB to_TO a_DT clinical_JJ audience_NN ,_,
        but_CC the_DT underlying_VBG message_NN to_TO clinicians_NNS could_MD not_RB be_VB more_RBR important_JJ :_: that_IN ,_, currently_RB ,_,
        studies_NNS involving_VBG large_JJ datasets_NNS ,_, especially_RB ones_NNS that_WDT have_VBP a_DT clinical_JJ outcome_NN ,_, are_VBP so_RB
        poorly_RB reported_VBD (_( or_CC possibly_RB so_RB poorly_RB done_VBN )_) that_IN many_JJ are_VBP not_RB reproducible_JJ ._. This_DT problem_NN
        was_VBD also_RB the_DT topic_NN of_IN a_DT recent_JJ meeting_NN in_IN Heidelberg_NNP ,_, “ Best_JJS Practice_NNP in_IN Microarray_NNP Studies_NNPS”
        (_( http_NN :_: /_NN /_NN www_NN ._. biometrie_NN ._. uni-heidelberg_JJ ._. de_IN /_NN workshops_NNS /_NN bestpractice_NN /_NN index_NN ._. htm_NN )_) ._.
        As_IN microarrays_NNS have_VBP become_VBN mainstream_NN research_NN tools_NNS in_IN biology_NN and_CC medicine_NN ,_, the_DT large_JJ
        datasets_NNS and_CC complex_JJ analyses_NNS from_IN these_DT studies_NNS have_VBP presented_VBN challenges_NNS :_: for_IN authors_NNS in_IN
        analyzing_VBG the_DT data_NNS ,_, for_IN reviewers_NNS and_CC editors_NNS in_IN deciding_VBG on_IN the_DT suitability_NN of_IN papers_NNS for_IN
        publication_NN ,_, for_IN journals_NNS in_IN determining_VBG how_WRB much_JJ data_NNS needs_VBZ to_TO be_VB presented_VBN within_IN the_DT
        paper_NN itself_PRP ,_, for_IN other_JJ researchers_NNS in_IN reproducing_VBG the_DT data_NNS ,_, and_CC ,_, finally_RB ,_, for_IN readers_NNS in_IN
        deciding_VBG how_WRB to_TO assess_VB the_DT data_NNS presented_VBN ._. The_DT results_NNS from_IN several_JJ high-profile_JJ papers_NNS
        have_VBP already_RB proved_VBN difficult_JJ to_TO reproduce_VB ,_, even_RB by_IN those_DT with_IN sufficient_JJ time_NN and_CC
        computing_NN expertise_NN ._.
        Where_WRB do_VBP such_JJ analyses_NNS leave_VBP the_DT new_JJ science_NN of_IN molecular_JJ pathology_NN ?_. Ruschhaupt_NNP and_CC
        colleagues_NNS comment_VB that_IN “ the_DT literature_NN on_IN the_DT induction_NN of_IN prognostic_JJ profiles_NNS from_IN
        microarray_NN studies_NNS is_VBZ a_DT methodological_JJ wasteland_NN ._.” Much_JJ the_DT same_JJ could_MD be_VB said_VBN of_IN other_JJ
        applications_NNS of_IN molecular_JJ biology_NN to_TO clinical_JJ samples_NNS ._. A_DT systematic_JJ review_NN of_IN molecular_JJ and_CC
        biological_JJ tumor_NN markers_NNS in_IN neuroblastoma_NN (_( Clin_NNP Cancer_NNP Res_NNP 10_CD :_: 4_CD –_NN 12_CD )_) found_VBD that_IN its_PRP$
        conclusions_NNS were_VBD limited_VBN by_IN “ small_JJ sample_NN sizes_NNS ,_, poor_JJ statistical_JJ reporting_NN ,_, large_JJ
        heterogeneity_NN across_IN studies_NNS …_NN and_CC publication_NN bias_NN ._.” John_NNP Ioannidis_NNP and_CC colleagues_NNS (_( Lancet_NNP
        362_CD :_: 1439_CD –_NN 1444_CD )_) did_VBD a_DT similar_JJ analysis_NN of_IN 30_CD microarray_NN studies_NNS with_IN major_JJ clinical_JJ
        outcomes_NNS in_IN cancer_NN ._. They_PRP showed_VBD that_IN the_DT studies_NNS were_VBD small—median_NN sample_NN size_NN was_VBD 25_CD
        patients_NNS ,_, and_CC validation_NN was_VBD incomplete_JJ in_IN most_JJS studies_NNS ._. They_PRP recommended_VBD that_IN molecular_JJ
        prognostic_JJ studies_NNS be_VB classified_VBN as_IN phase_NN 1_CD (_( early_JJ exploratory_JJ probing_VBG associations_NNS )_) ,_, phase_NN
        2_CD (_( exploratory_JJ with_IN extensive_JJ analyses_NNS )_) ,_, or_CC phase_NN 3_CD (_( large_JJ confirmatory_NN studies_NNS with_IN
        pre-stated_JJ hypotheses_NNS and_CC precise_JJ quantification_NN of_IN the_DT magnitude_NN of_IN the_DT effect_NN )_) ,_, and_CC that_IN
        only_JJ studies_VBZ that_WDT had_VBD undergone_VBN phase_NN 3_CD testing_NN should_MD be_VB considered_VBN robust_JJ enough_RB for_IN use_NN
        in_IN clinical_JJ practice_NN ._. Most_JJS current_JJ studies_NNS should_MD be_VB considered_VBN as_IN phase_NN 1_CD or_CC ,_, at_IN best_JJS ,_,
        phase_NN 2_CD ._.
        So_RB ,_, despite_IN considerable_JJ hype_NN ,_, the_DT published_VBN studies_NNS are_VBP far_RB from_IN the_DT level_NN of_IN evidence_NN
        that_WDT would_MD be_VB accepted_VBN for_IN virtually_RB any_DT other_JJ medical_JJ test_NN ._. In_IN a_DT review_NN in_IN 2003_CD
        (_( Hematology_NNP [_NN Am_NNP Soc_NNP Hematol_NNP Educ_NNP Program_NNP ]_NN 2003_CD :_: 279_CD –_NN 293_CD )_) ,_, Rita_NNP Braziel_NNP and_CC colleagues_NNS
        concluded_VBD ,_, “ rapid_JJ identification_NN and_CC neutralization_NN of_IN spurious_JJ results_NNS is_VBZ essential_JJ to_TO
        prevent_VB them_PRP from_IN becoming_VBG accepted_VBN facts_NNS ._.”
        But_CC these_DT problems_NNS are_VBP not_RB new_JJ in_IN medical_JJ research_NN ._. In_IN 1994_CD (_( BMJ_NNP 308_CD :_: 283_CD –_NN 284_CD )_) ,_, Doug_NNP
        Altman_NNP ,_, who_WP was_VBD instrumental_JJ in_IN developing_VBG the_DT CONSORT_NNP guidelines_NNS for_IN reporting_NN of_IN clinical_JJ
        trials_NNS ,_, said_VBD that_IN “ huge_JJ sums_NNS of_IN money_NN are_VBP spent_VBN annually_RB on_IN research_NN that_WDT is_VBZ seriously_RB
        flawed_VBN through_IN the_DT use_NN of_IN inappropriate_JJ designs_NNS ,_, unrepresentative_JJ samples_NNS ,_, small_JJ samples_NNS ,_,
        incorrect_JJ methods_NNS of_IN analysis_NN ,_, and_CC faulty_JJ interpretation_NN ,_,” and_CC “ that_DT quality_NN control_NN needs_VBZ
        to_TO be_VB built_VBN in_IN from_IN the_DT start_NN rather_RB than_IN the_DT failures_NNS being_VBG discarded_VBN ._.”
        So_RB how_WRB can_MD we_PRP ensure_VB that_IN the_DT wealth_NN of_IN data_NNS pouring_VBG out_IN of_IN microarray_NN and_CC other_JJ
        molecular_JJ diagnostic_JJ studies_NNS is_VBZ turned_VBN into_IN meaningful_JJ knowledge_NN ?_. The_DT Microarray_NNP Gene_NNP
        Expression_NNP Data_NNP Society_NNP has_VBZ proposed_VBN a_DT set_NN of_IN guidelines_NNS (_( MIAME_NNP )_) for_IN the_DT reporting_NN of_IN
        microarray_NN data_NNS ,_, and_CC that_IN all_DT such_JJ data_NN should_MD be_VB deposited_VBN in_IN public_JJ databases_NNS ._. But_CC as_IN
        Ruschhaupt_NNP and_CC others_NNS have_VBP shown_VBN ,_, disclosure_NN of_IN results_NNS and_CC data_NNS is_VBZ not_RB enough_RB ,_, since_IN there_EX
        is_VBZ little_JJ consensus_NN on_IN the_DT appropriate_JJ statistical_JJ analyses_NNS and_CC many_JJ are_VBP developed_VBN on_IN a_DT
        case_NN by_IN case_NN basis_NN ,_, which_WDT may_MD not_RB be_VB reproducible_JJ ,_, even_RB by_IN the_DT authors_NNS ._. Some_DT researchers_NNS
        advocate_VBP the_DT use_NN of_IN standard_JJ statistical_JJ packages_NNS ,_, which_WDT allows_VBZ the_DT reader_NN to_TO repeat_VB an_DT
        entire_JJ analysis_NN quickly_RB and_CC ,_, hence_RB ,_, assess_VBP the_DT robustness_NNS of_IN the_DT results_NNS ._. Some_DT authors_NNS have_VBP
        produced_VBN a_DT transcript_NN of_IN their_PRP$ statistical_JJ analyses_NNS as_IN a_DT supplement_NN to_TO their_PRP$ articles_NNS
        (_( e_SYM ._. g_SYM ._. ,_, Nucleic_NNP Acids_NNP Res_NNP 32_CD :_: e_SYM 50_CD )_) ._. At_IN the_DT very_RB least_JJS authors_NNS should_MD have_VB a_DT protocol_NN with_IN a_DT
        prespecified_JJ plan_NN for_IN patient_NN selection_NN and_CC statistical_JJ analysis—accepted_JJ practice_NN for_IN
        clinical_JJ trials_NNS ,_, but_CC not_RB yet_RB for_IN other_JJ medical_JJ research_NN ._. An_DT ultimate_JJ aim_NN for_IN reporting_VBG
        would_MD be_VB the_DT type_NN of_IN compendium_NN discussed_VBN by_IN Ruschhaupt_NNP and_CC colleagues—_NN“ an_DT interactive_JJ
        document_NN that_WDT bundles_NNS primary_JJ data_NNS ,_, statistical_JJ processing_NN methods_NNS ,_, figures_NNS ,_, and_CC derived_VBD
        data_NNS together_RB with_IN the_DT textual_NN documentation_NN and_CC conclusions_NNS ._.” One_CD such_JJ compendium_NN is_VBZ
        illustrated_VBN in_IN a_DT paper_NN by_IN Robert_NNP Gentleman_NNP (_( Stat_NNP Appl_NNP Genet_NNP Mol_NNP Biol_NNP 4_CD :_: article_NN 2_LS )_) ._. 
        PLoS_NNP Medicine_NNP is_VBZ keen_JJ to_TO work_VB with_IN authors_NNS towards_IN making_VBG such_JJ reporting_NN
        possible_JJ ._. But_CC although_IN the_DT time_NN might_MD have_VB gone_VBN when_WRB the_DT two-dimensional_JJ journal_NN article_NN
        could_MD suffice_VB for_IN complex_JJ papers_NNS ,_, clinicians_NNS should_MD nonetheless_RB apply_VB the_DT same_JJ critical_JJ
        assessment_NN that_IN they_PRP would_MD for_IN any_DT other_JJ clinical_JJ tool_NN ._. If_IN a_DT result_NN is_VBZ too_RB good_JJ to_TO be_VB true_JJ ,_,
        it_PRP probably_RB is_VBZ ._.
      
    
  
